

<b>FORM 1449 (Modified)</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>	Docket Number: 14669.0064USU1	Application Number: 10/800,291
	Applicant: Toth et al.	
	Filing Date: March 12, 2004	Group Art Unit: 1616

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NO.	DATE (mm-dd-yyyy)	COUNTRY	CLASS	SUBCLASS		
	WO 92/00293	01-09-1992	WIPO				
	WO 00/02560	01-20-2000	WIPO				
	EP 0 208 855	01-21-1987	EP				
	WO 95/01792	01-19-1995	WIPO				
	EP 1 507 531	01-24-2007	EP				
NON-PATENT DOCUMENTS							
	Arguments filed October 24, 2007 by Quimica Sintetica, S.A.; Opponent of EP 1 507 531						
	An excerpt from the Opposition proceedings concerning EP 0 993 455						
	Clinical Pharmacology and Biopharmaceutics Review" published on December 21, 2001 on the FDA website for Clarinex (tablets 5 mg desloratadine); published December 21, 2001						
	European Public Assessment Report (EPAR) of the EMEA of Aerious (film-coated tablets 5 mg desloratadine); January 16, 2001						

EXAMINER:     /Nathan Schlientz/	DATE CONSIDERED     11/26/2008
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

<b>23552</b> <small>PATENT TRADEMARK OFFICE</small>
--